Gilde Healthcare

Gilde Healthcare Partners B.V. is a private equity and venture capital firm based in Utrecht, Netherlands, with additional offices in Cambridge, Massachusetts, and Frankfurt am Main, Germany. Established in 2000, the firm specializes in investing in the healthcare sector, focusing on healthcare technology, medtech, diagnostics, digital health, therapeutics, and healthcare services. Gilde Healthcare targets lower mid-market companies and seeks to lead investments, typically investing between €1 million and €35 million in firms with enterprise values up to €150 million. The firm emphasizes sectors such as biopharma, medical devices, clinical decision support, and various healthcare services, including primary and specialized care. Gilde Healthcare aims to take both majority and minority stakes in its portfolio companies and actively participates in their management by securing board positions. The firm primarily invests in the United States and Europe, particularly in the Benelux region.

Dirkjan Beugelsdijk

Finance Director

Josephine Bogaerts

Senior Associate, Private Equity

Arthur Franken

Partner

Jasper van Gorp

Managing Partner

Edwin de Graaf

Managing Partner

Karl Hofbauer

Operational Partner

Job Komen

Partner

Stefan Luzi

Partner

Pieter van der Meer

Managing Partner and Founder

Mika Nishimura

Operational Partner

Marc Olivier Perret

Managing Partner

Herbert Pinedo

Operational Partner

Tom Klein Robbenhaar

Partner, Investment Manager

Robert Stein

Partner, Private Equity

Matthew Vessa

Vice President

Geoffrey Waters

Operational Partner

Paul West

Operational Partner

Sonia Hallen

Investment Manager, Therapeutics, Venture&Growth

Past deals in Medical Devices

Shoulder Innovations

Series E in 2025
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leverages this technology to create simple surgical instrumentation, which reduces operative time and cost. Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery.

Alleviant Medical

Venture Round in 2025
Alleviant Medical focuses on developing a minimally-invasive medical device to treat congestive heart failure. Its proprietary transcatheter technology is designed to create a paradigm shift in the treatment of heart failure by relieving patient symptoms, improving quality of life, and reducing hospital readmissions for over 6 million Americans currently suffering from this disease.

Moximed

Series D in 2024
Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Argá Medtech

Series B in 2024
Argá Medtech specializes in the development of an innovative cardiac ablation system aimed at treating cardiac arrhythmias, particularly ventricular tachycardia. The company has created a proprietary coherent sine-burst electroporation system that enhances treatment effectiveness through increased power and depth. This advanced technology features an innovative catheter design that eliminates the need for exchanges, thereby improving flexibility and efficiency in clinical applications. As a result, Argá Medtech's solutions enable healthcare professionals to optimize therapeutic outcomes and streamline the treatment process for patients suffering from arrhythmias.

Mainstay Medical

Private Equity Round in 2024
Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

Fire1

Venture Round in 2023
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Shoulder Innovations

Series D in 2023
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leverages this technology to create simple surgical instrumentation, which reduces operative time and cost. Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery.

Moximed

Series C in 2022
Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Chr. Diener

Acquisition in 2022
Chr. Diener is a contract manufacturer of customer-specific precision surgical instruments.

ProVerum

Series A in 2022
ProVerum Medical is a medtech company focused on developing innovative minimally invasive devices for the treatment of benign prostatic hyperplasia (BPH). Its technology offers a safer and more effective approach to BPH treatment, allowing patients to receive care in a doctor's office or operating room with reduced invasiveness compared to traditional methods. The device addresses the enlargement of the prostate gland, which can lead to urinary difficulties, by being placed inside the urethra to restore normal urinary function. This advancement enables healthcare providers to offer improved treatment options for patients suffering from this condition.

KLIFO

Acquisition in 2021
KLIFO is a consulting firm specializing in drug development, partnering with biotechnology and pharmaceutical companies to enhance their drug development projects. The company provides comprehensive solutions across various aspects of clinical research, including clinical operations, clinical trial supply, regulatory affairs, and pharmacovigilance. KLIFO also focuses on the development of pharmaceutical and biotech products as well as medical devices. By leveraging its multidisciplinary expertise, KLIFO aims to help its partners maximize opportunities, mitigate risks, and drive innovation, thereby facilitating efficient project advancement in the life sciences sector.

CVRx

Venture Round in 2020
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

CVRx

Series G in 2019
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

Vesper Medical

Venture Round in 2019
Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet the multiple anatomical challenges presented by vein mechanics. Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA.

Inari Medical

Series C in 2018
Inari Medical, Inc. is a commercial-stage medical device company headquartered in Irvine, California, that specializes in developing innovative products for patients with venous diseases. Founded in 2011, the company focuses on treating venous thromboembolism through its advanced catheter-based mechanical thrombectomy devices. The ClotTriever system is designed for the safe and effective removal of large blood clots from peripheral blood vessels, specifically targeting deep vein thrombosis. The FlowTriever system addresses pulmonary embolism by removing clots from the pulmonary arteries. Both devices are FDA-cleared and aim to improve the quality of life for patients by eliminating the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States, while also engaging in international markets.

Fire1

Series C in 2018
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Vapotherm

Series D in 2017
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients experiencing respiratory distress. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocities through a small-bore nasal interface. In addition to these systems, Vapotherm provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for air supply, and aerosol delivery accessories. The company aims to enhance clinical outcomes while improving patient comfort and compliance, and it primarily sells its products to hospitals through a direct sales organization in the United States and select international distributors. Founded in 1993, Vapotherm continues to focus on innovative solutions that enhance the quality of life for patients of all ages.

Nightbalance

Series B in 2016
NightBalance B.V. is a company established by alumni of TU Delft, originating from research conducted at the Delft University of Technology in 2007 focused on enhancing positional therapy aids. Founded in 2009, NightBalance specializes in the development of the Sleep Position Trainer, a smart therapeutic device designed to address sleep apnea. This innovative therapy monitors patients' sleep behavior and actively prevents positional obstructive sleep apnea, allowing individuals to achieve more comfortable and restful sleep.

STAT-Dx

Series C in 2016
STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.

Moximed

Series B in 2016
Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

BionX™ Medical Technologies

Series E in 2015
BiOM (fromerly iWalk) is a Massachusetts based company whose sole product is the PowerFoot One. The Powerfoot One has two powerful microprocessors and six environmental sensors evaluate and adjust ankle position, stiffness, damping and power thousands of times a second. Control algorithms generate human-like force while traversing level ground, slopes and stairs, providing active amputees with near-normal gait and lower energy expenditure compared to state-of-the-art passive prosthetics.

Vapotherm

Series C in 2015
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients experiencing respiratory distress. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocities through a small-bore nasal interface. In addition to these systems, Vapotherm provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for air supply, and aerosol delivery accessories. The company aims to enhance clinical outcomes while improving patient comfort and compliance, and it primarily sells its products to hospitals through a direct sales organization in the United States and select international distributors. Founded in 1993, Vapotherm continues to focus on innovative solutions that enhance the quality of life for patients of all ages.

Moximed

Series B in 2015
Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Vapotherm

Series B in 2014
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients experiencing respiratory distress. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocities through a small-bore nasal interface. In addition to these systems, Vapotherm provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for air supply, and aerosol delivery accessories. The company aims to enhance clinical outcomes while improving patient comfort and compliance, and it primarily sells its products to hospitals through a direct sales organization in the United States and select international distributors. Founded in 1993, Vapotherm continues to focus on innovative solutions that enhance the quality of life for patients of all ages.

Viroclinics Biosciences

Acquisition in 2014
Viroclinics Biosciences is a leading contract research and clinical laboratory service company providing diagnostic and preclinical studies along with drug development for prevention and treatment of virus infections. With our extensive experience in respiratory viruses, in particular influenza, our mission is to improve human and animal health by serving the biopharmaceutical community with state-of-the-art diagnostics, custom-made models in (pre)clinical drug testing, and expert advice on development of antivirals and vaccines. We offer a full range of virology services for new drug development programs and post-marketing surveillance of existing drugs and vaccines, ranging from traditional virology assays to the latest deep sequencing protocols for a very broad range of viruses. Our BSL2 and BSL3 labs enable us to perform analysis according to international ISO 15189 accreditation. Close cooperation with the Erasmus MC Viroscience lab brings the combined benefits of a broad range of knowledge, experience and skills to our work

Sapiens Steering Brain Stimulation

Series C in 2013
Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.

BionX™ Medical Technologies

Series D in 2012
BiOM (fromerly iWalk) is a Massachusetts based company whose sole product is the PowerFoot One. The Powerfoot One has two powerful microprocessors and six environmental sensors evaluate and adjust ankle position, stiffness, damping and power thousands of times a second. Control algorithms generate human-like force while traversing level ground, slopes and stairs, providing active amputees with near-normal gait and lower energy expenditure compared to state-of-the-art passive prosthetics.

Moximed

Venture Round in 2012
Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Inova Labs

Series B in 2011
Inova Labs, Inc. operates as a medical device development, manufacturing, and worldwide distribution company. It primarily focuses on direct patient care products. The company offers LifeChoice, a stationary and portable oxygen concentrator with a pulse mode system for patients requiring 1, 2, or 3LPM of supplemental oxygen; and accessories, including carrying cases, external batteries, and DC and AC power adapters. It sells its products through authorized providers on their Websites. The company was founded in 2002 and is based in Austin, Texas.

MTM Laboratories

Series C in 2009
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.

BG Medicine

Series D in 2008
BG Medicine, Inc. is a life sciences company based in Waltham, Massachusetts, focused on the development and commercialization of diagnostic products aimed at guiding the treatment of patients with heart failure and related disorders. The company offers the BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 levels in serum or plasma, and the CardioSCORE Test, a multi-analyte blood test designed to assess the near-term risk of atherothrombotic cardiovascular events, such as heart attacks and strokes. BG Medicine has established partnerships with several prominent firms, including Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc., to develop automated versions of its tests and related assay kits. Founded in 2000, BG Medicine was previously known as Beyond Genomics, Inc. and rebranded in 2004.

FlowCardia

Series C in 2007
FlowCardia, Inc. is a medical device company established in 2002, specializing in the design and development of catheter-based technologies aimed at overcoming chronic total occlusions (CTOs) in coronary and peripheral arteries. CTOs present significant challenges in interventional therapy, often resulting in patients being referred for more invasive procedures such as bypass surgery or limb amputation due to the lack of effective recanalization devices. FlowCardia's innovative solutions seek to address this critical gap in treatment options, enhancing the safety and efficacy of procedures for patients with these difficult-to-treat conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.